Press Release | January 20, 2021 | BIO Statements, Cancer/Oncology, Patient Advocacy, Therapeutic Areas, Autoimmune, Psychiatry, Medicare Part D, Cost & Value of Biopharmaceuticals
In his last day in office, former President Donald Trump proposed a sweeping change to Medicare’s “Part D” drug benefit. Billed as a demonstration project through the Centers for Medicare and Medicaid Innovation (CMMI), this new policy would allow insurance plans to cover fewer “protected” drugs in…